undamentalytics Newsletter
Sign in

Seres Therapeutics, Inc. income statement

In fiscal 2025, Seres Therapeutics, Inc. reported revenue of $789,000, operating income of −$94.0m (a -11910.1% margin) and net income of $5.7m, or $0.64 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0223228353314570012
Research and development388289968091142110118654947
General and administrative173334332531697078533932
Operating income−55−93−91−100−72−88−64−180−195−121−94−84
Interest expense————1336200—
Net interest income012—————————
Income tax000000000000
Net income−55−92−89−99−70−89−66−250−11406−22
Diluted EPS−$46.60−$46.00−$44.20−$48.60−$24.80−$22.40−$14.40−$46.20−$17.77$0.00$0.64−$2.41
Diluted shares (average)1m2m2m2m3m4m5m5m6m8m9m9m
EBITDA−54−89−84−92−64−82−59−173−189−116−90−81

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: KRSA vs MCRBMCRB vs OVIDABSI vs MCRB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Seres Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Seres Therapeutics, Inc.